Capula Management Ltd acquired a new position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 35,670 shares of the biotechnology company's stock, valued at approximately $320,000.
Several other hedge funds and other institutional investors also recently modified their holdings of AUPH. SBI Securities Co. Ltd. acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $25,000. Blue Trust Inc. raised its position in Aurinia Pharmaceuticals by 3,041.4% during the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company's stock worth $57,000 after buying an additional 6,174 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter worth $96,000. Cibc World Markets Corp purchased a new stake in shares of Aurinia Pharmaceuticals in the fourth quarter valued at about $113,000. Finally, FMR LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company's stock valued at $93,000 after acquiring an additional 3,919 shares in the last quarter. 36.83% of the stock is currently owned by hedge funds and other institutional investors.
Aurinia Pharmaceuticals Price Performance
NASDAQ:AUPH traded up $0.07 during trading hours on Friday, hitting $7.41. The company's stock had a trading volume of 1,384,955 shares, compared to its average volume of 1,357,516. The company has a market capitalization of $1.02 billion, a PE ratio of -49.40 and a beta of 1.20. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67. The business's 50-day moving average is $8.01 and its two-hundred day moving average is $8.10. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.
Wall Street Analyst Weigh In
Separately, StockNews.com upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.
Get Our Latest Analysis on Aurinia Pharmaceuticals
Insider Activity at Aurinia Pharmaceuticals
In other Aurinia Pharmaceuticals news, insider Greg Keenan sold 8,305 shares of the business's stock in a transaction on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the sale, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. The trade was a 5.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph M. Miller sold 61,859 shares of the firm's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the transaction, the chief financial officer now owns 633,515 shares of the company's stock, valued at approximately $5,068,120. This represents a 8.90 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 343,898 shares of company stock worth $2,753,094 over the last 90 days. Company insiders own 4.30% of the company's stock.
Aurinia Pharmaceuticals Company Profile
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Further Reading
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
